Skip to main content
. 2022 Nov 9;27(22):7719. doi: 10.3390/molecules27227719

Table 4.

In vitro VGFER-2 inhibition, cytotoxicity, and safety of the target compound 10.

HepG2
IC50 (µM)
SI (HepG2) MCF-7
IC50 (µM)
SI (MCF-7) W-38
IC50 (µM)
VEGFR IC50 (nM)
Compound 10 21.00 1.55 26.10 1.25 32.57 65.83
Sorafenib 5.96 2.77 8.45 1.95 16.49 61.65